Exhibit 99.2

 

Arcadia Biosciences, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except share data and per share data)

	Three Months Ended March 31,
		2023			2022
Revenues:
Product	$	1,509		$	3,170
Royalty		—			50
Total revenues		1,509			3,220
Operating expenses (income):
Cost of revenues		825			3,458
Research and development		359			395
Change in fair value of contingent consideration		—			(31	)
Gain on sale of property and equipment		(19	)		(328	)
Selling, general and administrative		4,392			4,349
Total operating expenses		5,557			7,843
Loss from operations		(4,048	)		(4,623	)

# # #

1